multi-epitope folate receptor alpha-loaded dendritic cell vaccine

Biologicalexperimental

Clinical trial activity

3 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Apr 1, 2014 (NCT02111941)

Timeline

2020s

  1. Jan 1, 2023

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2024

    Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • multi-epitope folate receptor alpha-loaded dendritic cell vaccine

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06639074Phase 2Nov 12, 2024Mayo Clinic
NCT05920798Phase 1/Phase 2 (Phase 2)Sep 28, 2023Mayo Clinic
NCT02111941N/AApr 1, 2014Mayo Clinic, National Cancer Institute (NCI)
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Mayo ClinicAcademic/Hospital3322014
National Cancer Institute (NCI)Government1012014
2 organizations
Page 1 / 1